不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
单细胞 RNA 测序探索无治疗缓解的慢性髓系白血病患者外周血 NK 细胞组成
英文原题：Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
查看英文原题
Single-cell RNA sequencing to explore composition of peripheral blood NK cells in patients with chronic myeloid leukemia in treatment-free remission.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究旨在探索 NK 细胞亚群及基因表达在维持 TFR 状态中的作用。我们在两组（健康对照和处于 TFR 状态的患者）的 PBMC 中鉴定出 6 种 NK 细胞。基因本体分析显示，上调基因富集于“免疫应答”“对肿瘤细胞的反应”和“细胞溶解”等类别。此外，两组中成熟和终末分化 NK 细胞、CD56 明亮型 NK 细胞及过渡型 NK 细胞这 3 个亚群均有多个显著上调基因；CML-TFR 患者的 CD56 明亮型和过渡型 NK 细胞处于增殖和活化状态。通过单细胞 RNA 测序分析，我们确认成熟和终末分化、CD56 明亮型及过渡型 NK 细胞亚群在维持 CML 患者 TFR 中发挥不可或缺的作用。
展开英文摘要原文
This study was to explore the role of NK cell subsets and gene expression in maintaining TFR status.
We identified six types of NK cells in the PBMCs over both groups (healthy controls and patients with TFR). Gene Oncology analysis showed that up regulated genes were enriched in the categories of "immune response," "reaction to tumor cells," and "cytolysis."
In addition, we found that the three NK cell subsets, mature and terminal NK cells, CD56 bright NK cells, and transitional NK cells, contained many significantly up regulated genes in both groups, and that CD56 bright NK cells and transitional NK cells in patients with CML-TFR were in a proliferating and activated state. Through single-cell RNA sequencing analysis, we confirmed that the mature and terminal, CD56 bright, and transitional subsets of NK cells play an indispensable role in maintaining TFR in patients with CML.
论文信息
- 作者
- Yu G、Lu W、Chen X、Li Y、Long J、Zheng Z、Yin C、Xu D
- 单位
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Leukemia & lymphoma2022 Nov
- 原文标识
- PubMed 35695125 · DOI 10.1080/10428194.2022.2086243